Kondo R, et al. - Chemotherapy with irinotecan plus cisplatin has shown promise in chemo-naïve small-cell lung cancer (SCLC) patients. In this phase II study, a high objective response rate and long survival were reported among previously treated SCLC patients with at least one platinum-based regimen, assigned to irinotecan (100 mg/m²) on days 1 and 8, every 3 weeks, until disease progression. Furthermore, patients well-tolerated the irinotecan monotherapy schedule and it could be an active treatment option for these patients.